Farnesol induces apoptosis of DU145 prostate cancer cells through the PI3K/Akt and MAPK pathways

JIN SOO PARK, JUNG KI KWON, HYE RI KIM, HYEONG JIN KIM, BYEONG SOO KIM and JI YOUN JUNG

Department of Companion and Laboratory Animal Science, Kongju National University, Yesan, Chungnam 340702, Republic of Korea

Received October 7, 2013; Accepted February 13, 2014

DOI: 10.3892/ijmm.2014.1679

Abstract. The aim of this study was to investigate the effect of farnesol on the induction of apoptosis in DU145 prostate cancer cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay showed that cell proliferation decreased significantly in a dose- and time-dependent manner. 4',6-Diamidino-2-phenylindole staining showed that chromatin condensation in cells treated with 60 μM of farnesol was markedly higher than in the control groups. Farnesol increased the expression of p53, p-c-Jun N-terminal kinase, cleaved-caspase-3, Bax, and cleaved-caspase-9, but decreased the expression of p-phosphatidylinositol-3-kinase-3-kinase (PI3K), p-Akt, p-p38, Bcl-2, and p-extracellular signal-regulated protein kinase, in a dose-dependent manner. The apoptotic cell ratio increased in a dose-dependent manner. The tumor growth inhibitory effect of farnesol was investigated in a mouse model. Compared to the control group, tumor volume decreased significantly in the group administered 50 mg/kg farnesol. Apoptosis was frequently detected in this same group with terminal deoxynucleotidyl transferase dUTP nick-end labeling assay. The results indicated that farnesol induced apoptosis of DU145 prostate cancer cells through the PI3K/Akt and mitogen-activated protein kinase signaling pathways.

Introduction

A high incidence of lung, breast, prostate, and colorectal cancers has been previously reported (1). Prostate cancer continues to be a major problem in developing countries, the United States and Europe (2,3). In western countries it is a common malignancy and the third most frequently diagnosed form of cancer in males (1,3). In the United States, prostate cancer is the second leading cause of cancer mortality in males (4). In 2012 an estimated 241,740 males in the United States were diagnosed with prostate cancer, and ~28,660 of those cases resulted in death (5). Prostate cancer also accounts for ~24% of new case diagnoses and 13% of cancer deaths in the United Kingdom (6). Although the pathogenesis of prostate cancer has not yet been determined, some known contributing risk factors include age, ethnicity and diet (7).

Developing prostate cancers require immediate therapies due to their androgen dependency (8,9). However, 18-36 months after initial treatments most patients with prostate cancer become castration-resistant to androgen deprivation therapy, leading to metastasis and the development of hormone-refractory prostate cancer (2,10). When prostate cancer progresses from being androgen-dependent to -independent, the patient usually succumbs to the disease (11). Androgen-refractory prostate cancer is chemoresistant and grows prior to androgen-dependent cancer (12,13). For this reason, the development of innovative and effective therapeutic options that inhibit androgen-dependent and -independent prostate cancers is needed (3,14).

Isoprenoids are important for cell proliferation, apoptosis, cell differentiation, lipid biosynthesis, and cell cycle arrest (15-24). Sterol and non-sterol isoprenoids are essential for a number of cell functions, including cell signaling, protein synthesis, maintaining membrane integrity, cell proliferation and apoptosis (22). Both types of isoprenoid are natural products produced from a commonplace precursor, mevalonate. Farnesol is a non-sterol isoprenoid produced by the dephosphorylation of farnesol pyrophosphate, a catabolite of the cholesterol biosynthetic pathway (22,23).

Farnesol is a 15-carbon isoprenoid found in a variety of plant products, such as orange peel, lemon-grass oil, strawberries and chamomile (25-27). Farnesol has been shown to have anti-bacterial (28,29), anticancer (16,21,30,31) and olfactory nerve effects (32). The anticancer action of farnesol has been reported to be mediated by farnesoid X receptor activity (33), wherein it induces the expression of thyroid hormone receptor-β1 mRNA, regulates gene transcription (34), and facilitates the activities of peroxisome proliferator-activated receptor-α and -γ (35).

The phosphatidylinositol-3-kinase (PI3K)/serine/threonine kinase (Akt) signaling pathway is essential for the mediation of several cell activities, including cell proliferation, growth, the inflammatory response, chemotaxis, survival and apop-
tosis (36,37). Increased activation of the PI3K/Akt signaling pathway is involved in the development of malignant tumors and resistance to chemotherapy (38). In addition, activation of Akt frequently occurs in endometrial and pancreatic cancers and has been linked to a poor prognosis (39-42). In vitro and in vivo studies have reported that inhibition of the PI3K/Akt signaling pathway is important for the success of chemotherapy-induced apoptosis of pancreatic cancer cells (43-45).

Mitogen-activated protein kinases (MAPKs) are serine/threonine-specific. They interrupt intracellular signaling related to a variety of activities, including cell proliferation, cell survival, cell death and transformation (46,47). MAPKs respond to extracellular stimuli such as growth factors, cytokines, and stress (48). The activities of the major members of the MAPK family, i.e., mitogen-activated protein kinase (p38), extracellular signal-regulated protein kinase 1/2 (ERK1/2), and c-Jun N-terminal kinase (JNK), are regulated by different MAPK cascades (49).

The primary aim of this study was to identify the mechanism of farnesol-induced apoptosis in DU145 prostate cancer cells. Analysis of cell viability by 4,6-diamidino-2-phenylindole (DAPI) staining and Annexin V/propidium iodide (PI) staining determined that farnesol-induced death of DU145 prostate cancer cells was due to apoptosis. The protein levels of phosphorylated JNK, phosphorylated ERK, phosphorylated p38, p53, Bcl-2, Bax, cleaved caspase-3, and phosphorylated Akt were also determined. In vivo, tumor size was measured twice per week for up to 5 weeks. Farnesol-induced cell death was also examined by the terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling (TUNEL) assay.

Materials and methods

Cells, materials, antibodies and reagents. Human prostate cancer DU145 cells were obtained from the Korean Cell Bank. Farnesol (Fig. 1) and 3-(4,5-dimethyl-2-yi)-2,5-diphenyl tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). RPMI-1640 medium, trypsin-EDTA, penicillin-streptomycin, and fetal bovine serum (FBS) were obtained from HyClone Laboratories (Logan, UT, USA). Primary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Dimethyl sulfoxide (DMSO) was purchased from Merck (Darmstadt, Germany). Tween-20 was purchased from Sigma-Aldrich. Cell lysis buffer and DAPI were obtained from Invitrogen (Carlsbad, CA, USA). A fluorescein isothiocyanate (FITC)-conjugated Annexin V apoptosis detection kit was purchased from BD Biosciences (San Diego, CA, USA).

Preparation of farnesol and cell culture. Farnesol was dissolved in a 1:14.6 mixture of Tween-20 and DMSO prior to administration. Final concentrations ranged from 0 to 100 µM. Test agents were added to the culture medium at concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 µM with a final DMSO concentration of <0.1%.

DU145 cells were cultured in RPMI-1640 supplemented with 10% FBS, 100 µg/ml penicillin and 100 µg/ml streptomycin in 5% CO₂ at 37°C. Cells were then subcultured in a 175-cm² flask (Nunc, Fisher Scientific, Loughborough, UK) at a density of 80-90%.

Cell viability assay. The effect of farnesol on DU145 cell survival was determined by MTT assay. Cells were seeded in 96-well microplates at two densities: wells containing 2x10⁴ cells/ml were incubated for 24 h and those containing 1x10⁵ cells/ml were incubated for 48 h. The two groups underwent treatment with 0-100 µM farnesol. Following incubation, the medium was removed and the cells were incubated for 2 h with 40 µl of a solution containing 5 mg/ml MTT in phosphate-buffered saline (PBS). Then, 100 µl of DMSO was added to each well to dissolve the formazan crystal. Absorbance at 570 nm was measured using an ELISA reader (Bio-Rad, Hercules, CA, USA). Cell viability was expressed as the ratio of optical density values of the treatment and control groups.

Nuclear morphology. To assess the extent of apoptosis, DU145 cell nuclei were stained with DAPI and observed using fluorescence microscopy. DU145 cells were seeded in 12-well microplates at a density of 4x10⁴ cells/well and incubated for 24 h with 0, 30 or 60 µM farnesol. Following treatment the cells were fixed and incubated in PBS containing 4% paraformaldehyde for 30 min. After fixation, the cells were washed twice with PBS and nuclei were stained with DAPI. Fluorescence signals were visualized using a fluorescence microscope at a x200 magnification.

Western blotting. DU145 cells were incubated with 0, 30 or 60 µM farnesol for 24 h. Cells were harvested by washing the flasks once with ice-cold PBS and then treating cells for 3 min with trypsin-EDTA. Floating cells were collected, transferred to 50-ml conical centrifuge tubes, and centrifuged for 7 min at 260 x g. The resulting cell pellets were washed twice with PBS and resuspended in 200 µl of lysis buffer. Lysates were prepared and centrifuged at 15,920 x g for 5 min at 4°C.

Protein concentrations were determined by a Bradford protein assay (Bio-Rad). Protein (30 µg) was separated by 12% SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride membranes (Amersham Biosciences). The transferred membranes were blocked with Tris-buffered saline containing 5% non-fat dry milk and 0.1% Tween-20 for 2 h at 4°C. After blocking, but prior to incubation, the blocked membranes were treated individually with the following antibodies: anti-β-actin, anti-cleaved caspase-3, anti-cleaved caspase-9, anti-Bcl-2, anti-Akt, anti-phospho-Akt, anti-Bax, anti-phospho-PI3K, anti-phospho-JNK, anti-phospho-ERK, anti-phospho-p38 and anti-p53. Membranes were then incubated overnight with gentle agitation at 4°C.

Following incubation the membranes were washed with Tris-buffered saline containing 0.1% Tween-20, treated with secondary antibodies (horseradish peroxidase-conjugated goat anti-mouse or -rabbit IgG; Cell Signaling Technology), and incubated with gentle agitation at room temperature for 2 h. The membranes were washed once more with Tris-buffered saline containing 0.1% Tween-20, and bands were subsequently visualized using the ECL detection reagents (Pierce, Rockford, IL, USA).

Apoptosis analysis. Following treatment with farnesol, DU145 cell apoptosis was measured using an Annexin V staining kit (Becton-Dickinson, Franklin Lakes, NJ, USA). Cells were incubated with 0, 30 or 60 µM farnesol for 24 h and harvested
by exposure to trypsin-EDTA for 3 min. The harvested cells were washed once with PBS, resuspended in 100 µl of Annexin V binding buffer, and mixed with 5 µl of fluorescein isothiocyanate-conjugated Annexin V and phycoerythrin-conjugated PI. The resuspended cells were then incubated at room temperature in the dark for 15 min. The frequency of apoptotic cells was analyzed using a FACSCalibur™ flow cytometer (Becton-Dickinson).

**Animals.** Five-week-old male nude mice weighing 20-30 g were purchased from Orient Bio (Gyeonggi-do, Korea). They were maintained at 23±5°C and a relative humidity of 40±10% with artificial lighting from from 800 to 2,000 lx in an animal laboratory approved by the Companion and Laboratory Animal Science Department of Kong-Ju National University. The mice were housed in cages and allowed free access to autoclaved water, food and commercial rodent chow (Biopia, Seoul, Korea). Animal experiments were performed with the approval of the Institutional Animal Care and Use Committee and according to the guidelines of Kong-Ju National University.

**Xenografts.** DU145 cells were grown in media composed of RPMI-1640 supplemented with 10% FBS, 100 µg/ml penicillin and 100 µg/ml streptomycin. The cells were then harvested by washing with ice-cold PBS and exposure to trypsin-EDTA. Collected cells were washed twice with PBS and resuspended in RPMI-1640 medium.

DU145 prostate cancer cells at a density of 5x10⁶ cells/0.2-ml medium were injected subcutaneously into the flanks of donor nude mice. When the resulting tumors reached 2,000 mm³ in size, the mice were anesthetized with diethyl ether and the tumor masses were removed surgically. After slicing the mass into 2x2-mm sections, tumor fragments were implanted subcutaneously into the right flank of each mouse. After tumor implantation, mice were randomly divided into two groups (n=3 each).

**Preparation and administration of farnesol.** Three mice were divided randomly into different treatment groups. Oral treatment of each group began on the day of tumor fragment implantation and continued for 5 weeks. Control mice received 0.2-ml corn oil daily for 5 weeks. Mice in the treatment group received 50 mg/kg farnesol daily for 5 weeks.

**Measurement of tumor size.** Mice were observed for 5 weeks following tumor implantation. Tumor sizes were measured twice per week using vernier calipers (Mitutoyo, Kawasaki, Japan). Tumor sizes were calculated as: width² x length/2.

**TUNEL assay.** Apoptotic cells were detected using the Dead End™ Colorimetric TUNEL System (Promega, Madison, WI, USA). Tumor paraffin blocks were separated into 5-µm sections using a microtome (Shandon Inc., Pittsburgh, PA, USA) and attached to microscope slides.

**Statistical analysis.** Data were expressed as the means ± standard deviation (SD). One-way analysis of variance was used to analyze differences in multiple comparisons. P<0.05 was considered to indicate statistical significance.

**Results**

**Farnesol-induced inhibition of cell proliferation.** Treatment with farnesol results in inhibition of the proliferation of DU145 cells. The chemical structure of farnesol is shown in Fig. 1.

To determine the effect of farnesol on their growth, DU145 cells were treated with 0-100 µM farnesol for 24 or 48 h, and viability was determined by MTT assay (Fig. 2). Farnesol decreased the viability of DU145 cells in a dose- and time-dependent manner. In comparison to the control group, cell viability began to decrease significantly at 10 µM in the 24- and 48-h groups (P<0.05). The resulting cell viabilities after treatment with 30, 60 or 100 µM farnesol were 76.3±1.1, 60.0±1.7 and 8.1±2.8%, respectively ,at 24 h; and 56.3±2.3,
Farnesol increases chromatin condensation in DU145 prostate cancer cells. The cell proliferation results suggested that the number of dead cells increased in a dose- and time-dependent manner after farnesol treatment (Fig. 2). Chromatin condensation increased following treatment with 30 or 60 µM farnesol. DAPI staining distinguishes viable and apoptotic cells based on nuclear morphology. To investigate the chromatin condensation effects, DU145 cells were treated with 30 or 60 µM farnesol for 24 h and chromatin condensation was visualized by DAPI staining. Changes in the morphology of farnesol-treated DU145 cells were detected using a fluorescence microscope at a x200 magnification (Fig. 3A). Chromatin condensation was detected in DU145 cells treated with 30 or 60 µM farnesol in a dose-dependent manner. Characteristic apoptotic cell features were confirmed in DU145 cells treated with farnesol, including cytoplasmic condensation, loss of cell volume, nuclear fragmentation, convoluted nuclei, and apoptotic bodies. The untreated group did not exhibit features of apoptosis (Fig. 3A). These DAPI staining results suggested that farnesol induces apoptosis of DU145 cells in a dose-dependent manner.

Farnesol induces apoptosis in DU145 prostate cancer cells. The cause of farnesol-induced cell death was identified as apoptosis or necrosis. Apoptosis of DU145 cells treated with 30 or 60 µM farnesol was confirmed by Annexin V/PI double staining. As shown in Fig. 3B, farnesol induced apoptosis in DU145 cells in a dose-dependent manner. At 24 h treatment with 30 and 60 µM farnesol induced apoptosis in 11.79 and 14.55% of cells, respectively. Flow cytometry confirmed that farnesol induces apoptosis of DU145 prostate cancer cells.

Farnesol induces apoptosis through the PI3K/Akt pathway. The effect of farnesol on the PI3K/Akt pathway was subsequently examined. DU145 cells were treated with 30 or 60 µM farnesol for 24 h and apoptosis-related proteins assayed by western blotting. As shown in Fig. 4, PI3K phosphorylation was lower in the farnesol-treated group compared to the control group. The farnesol treatment group exhibited decreased Akt and Bcl-2 phosphorylation (Fig. 4).

By contrast, Bax, cleaved caspase-9 and cleaved caspase-3 levels increased in the farnesol-treated group (Fig. 4). These results suggested that farnesol induced apoptosis via inhibition of the PI3K/Akt pathway and activation of the caspase chain reaction.
Farnesol increases tumor suppressor gene p53 expression. p53 arrests the cell cycle (50,51) and induces apoptosis (52,53). p53 induces apoptosis by increasing the expression of apoptosis-related proteins (54-56). DU145 cells were treated with 30 or 60 µM farnesol for 24 h and the p53 level was assayed by western blotting. p53 expression was increased in the farnesol-treated group compared to the control group (Fig. 5).

Farnesol regulates the expression of MAPK pathway genes in DU145 prostate cancer cells. The three main MAPK members are stress-activated protein kinase JNK, stress-activated protein kinase 2 (p38), and ERK. MAPKs are associated with a variety of cellular activities.

The p38 MAPK signaling pathway is activated in cancer cells. Therefore, carcinostatic substances should inhibit activation of the p38 MAPK pathway. DU145 cells were treated with 30 or 60 µM farnesol for 24 h and p-JNK, p-p38 and p-ERK levels were determined by western blotting. As shown in Fig. 6, p-JNK expression was increased in the farnesol-treated group compared to the control group. However, the treatment group exhibited decreased levels of p38 and p-ERK phosphorylation. These results indicated that farnesol induced apoptosis via regulation of the MAPK pathway.

Farnesol inhibits the growth of DU145 prostate tumors. The apoptosis-inducing effects of farnesol in DU145 cells were confirmed prior to in vivo investigations using an animal model. To assess the antitumor effect of farnesol, a mouse xenograft model with DU145 prostate cancer cells was used. After subcutaneous inoculation of DU145 cells into athymic nude mice, farnesol was administered for 5 weeks and tumor sizes were measured at 2-day intervals. As shown in Fig. 7A, the tumor volume in animals treated with 50 mg/kg farnesol was reduced by 50% compared with the control group (P<0.05). The average tumor volumes at 5 weeks were 1,000 mm³ in the control group and 800 mm³ in the farnesol group (Fig. 7A). Administration of farnesol reduced tumor weights compared to the control group (Fig. 7B).

Discussion

Farnesol has been reported to induce cell death in numerous cancer cell lines (16,21,30,31). Several studies have demonstrated that farnesol also has anti-bacterial effects (28,29). However, the effect of farnesol in DU145 prostate cancer cells is not well understood. This study investigated the anticancer effects of farnesol in DU145 prostate cancer cells mediated by PI3K/Akt and MAPK signaling. Farnesol induced dose- and time-dependent apoptosis in DU145 prostate cancer cells.

To assess the effect of farnesol on the viability of DU145 cells, the MTT assay was performed. Farnesol significantly inhibited the growth of DU145 prostate cancer cells in a dose- and time-dependent manner (Fig. 2).

Apoptosis occurs as the result of a highly complex cascade of cellular events characterized by cell shrinkage, chromatin condensation and cell fragmentation (57,58). To investigate the effect of farnesol on chromatin condensation, DAPI staining...
was performed. As shown in Fig. 3A, the frequency of apoptotic bodies increased in the farnesol treatment group compared to the untreated group. Cells treated with 60 µM farnesol fluoresced more intensely, indicating chromatin condensation. Thus, farnesol potentially able to induce apoptosis.

The results of Annexin V/PI staining were similar. As shown in Fig. 3B, 24-h treatment with 30 and 60 µM farnesol induced apoptosis in 11.79 and 14.55% of the cells, respectively. These results indicate that farnesol increased apoptosis in a dose-dependent manner.

Western blot assays revealed that treatment of DU145 cells with farnesol altered the expression of PI3K/Akt pathway proteins. As shown in Fig. 4, farnesol treatment inhibited Akt and PI3K phosphorylation and decreased the level of Bcl-2. By contrast, Bax, cleaved caspase-3 and cleaved caspase-9 expression increased compared to the control group (Fig. 4), suggesting that farnesol induces apoptosis by altering the expression of PI3K/Akt pathway proteins.

p53 is a well-known tumor suppressor gene. Upregulation of p53 is associated with significant inhibition of Akt phosphorylation (59). As shown in Fig. 5, p53 activity increased following farnesol treatment. Therefore, farnesol induced apoptosis by the inhibition of p-Akt.

MAPKs are associated with a variety of cell activities, including cell proliferation, survival, death, and transformation (46,47). Western blotting was performed to determine the involvement of the MAPK pathway in farnesol-induced apoptosis. As shown in Fig. 6, expression of p-JNK was increased in the farnesol-treated group compared to the control group. By contrast, p-ERK and p-p38 levels decreased as a result of farnesol treatment. These results indicate that farnesol induces apoptosis by regulating proteins related to the MAPK pathway.

To determine its effects on DU145 prostate tumor volume, farnesol was administered to groups of 3 mice for 5 weeks. After 5 weeks tumor volumes were 35% lower in the farnesol-treated group compared to the control group (P<0.05) (Fig. 7A). Farnesol also significantly reduced tumor weight (Fig. 7B). TUNEL-positive cell numbers were increased in tumors from mice treated with farnesol compared to the control mice (Fig. 7C). These results suggest that farnesol significantly reduced tumor size, weight, and increased TUNEL-positive cell numbers (Fig. 7).
Collectively, the results of this study have shown farnesol to be a potential chemopreventive or therapeutic agent against DU145 prostate cancer.

Acknowledgements

This study was supported by the research grant of the Kongju National University in 2012.

References